Cargando…

HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer

We have shown that WT-161, a histone deacetylase 6 (HDAC6) inhibitor, shows remarkable anti-tumor activity in multiple myeloma (MM) in preclinical models. However, its activity in other type of cancers has not yet been shown. In this study, we further evaluated the biologic sequelae of WT161 in brea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hideshima, Teru, Mazitschek, Ralph, Qi, Jun, Mimura, Naoya, Tseng, Jen-Chieh, Kung, Andrew L., Bradner, James E., Anderson, Kenneth C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Priority Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655183/ https://www.ncbi.nlm.nih.gov/pubmed/29113288 http://dx.doi.org/10.18632/oncotarget.19019

Ejemplares similares

Correction: HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer
por: Hideshima, Teru, et al.
Publicado: (2021)

HDAC3 regulates DNMT1 expression in multiple myeloma: therapeutic implications
por: Harada, Takeshi, et al.
Publicado: (2017)

HDAC6 inhibitor WT161 induces apoptosis in retinoblastoma cells and synergistically interacts with cisplatin
por: Sun, Jun, et al.
Publicado: (2019)

HDAC6 inhibitor WT161 performs anti-tumor effect on osteosarcoma and synergistically interacts with 5-FU
por: Sun, Jun, et al.
Publicado: (2021)

Targeting the ‘garbage-bin’ to fight cancer: HDAC6 inhibitor WT161 has an anti-tumor effect on osteosarcoma and synergistically interacts with 5-FU
por: Sergi, Consolato M.
Publicado: (2021)

PRMT5 inhibitors on the (myeloma) road
por: Gulla, Annamaria, et al.
Publicado: (2018)

A MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells
por: Ischenko, Irene, et al.
Publicado: (2015)

The synergistic anticancer effect of the bromodomain inhibitor OTX015 and histone deacetylase 6 inhibitor WT-161 in osteosarcoma
por: Yu, Bo, et al.
Publicado: (2022)

IKKβ inhibitor in combination with bortezomib induces cytotoxicity in breast cancer cells
por: HIDESHIMA, HIROMASA, et al.
Publicado: (2014)

MYCN and HDAC5 transcriptionally repress CD9 to trigger invasion and metastasis in neuroblastoma
por: Fabian, Johannes, et al.
Publicado: (2016)

Signaling Pathway Mediating Myeloma Cell Growth and Survival
por: Hideshima, Teru, et al.
Publicado: (2021)

LTR12 promoter activation in a broad range of human tumor cells by HDAC inhibition
por: Krönung, Sonja K., et al.
Publicado: (2016)

Targeting histone deacetylase 3 (HDAC3) in the bone marrow microenvironment inhibits multiple myeloma proliferation by modulating exosomes and IL-6 trans-signaling
por: Ho, Matthew, et al.
Publicado: (2019)

Comparison of SARS-CoV-2 RT-PCR on a high-throughput molecular diagnostic platform and the cobas SARS-CoV-2 test for the diagnostic of COVID-19 on various clinical samples
por: Opota, Onya, et al.
Publicado: (2020)

Regulation of retinoic acid synthetic enzymes by WT1 and HDAC inhibitors in 293 cells
por: Li, Yifan, et al.
Publicado: (2017)

The biological significance of histone modifiers in multiple myeloma: clinical applications
por: Ohguchi, Hiroto, et al.
Publicado: (2018)

Author Correction: The biological significance of histone modifiers in multiple myeloma: clinical applications
por: Ohguchi, Hiroto, et al.
Publicado: (2021)

Carbonic anhydrase IX induction defines a heterogeneous cancer cell response to hypoxia and mediates stem cell-like properties and sensitivity to HDAC inhibition
por: Ledaki, Ioanna, et al.
Publicado: (2015)

The Interaction of SWI/SNF with the Ribosome Regulates Translation and Confers Sensitivity to Translation Pathway Inhibitors in Cancers with Complex Perturbations
por: Ulicna, Livia, et al.
Publicado: (2022)

HDAC2 negatively regulates memory formation and synaptic plasticity
por: Guan, Ji-Song, et al.
Publicado: (2009)

Sirtuin 6 deficiency induces endothelial cell senescence via downregulation of forkhead box M1 expression
por: Lee, Ok-Hee, et al.
Publicado: (2020)

RGS6 is an essential tumor suppressor that prevents bladder carcinogenesis by promoting p53 activation and DNMT1 downregulation
por: Yang, Jianqi, et al.
Publicado: (2016)

A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma
por: Hideshima, Teru, et al.
Publicado: (2008)

Small Molecule Multi-Targeted Kinase Inhibitor RGB-286638 Triggers P53-Dependent and -Independent Anti-Multiple Myeloma Activity through Inhibition of Transcriptional CDKs
por: Cirstea, Diana, et al.
Publicado: (2013)

HDAC6 Inhibitors Modulate Lys49 Acetylation and Membrane Localization of β-Catenin in Human iPSC-Derived Neuronal Cells
por: Iaconelli, Jonathan, et al.
Publicado: (2014)

Gain of function mutant p53 proteins cooperate with E2F4 to transcriptionally downregulate RAD17 and BRCA1 gene expression
por: Valenti, Fabio, et al.
Publicado: (2015)

The downregulation of putative anticancer target BORIS/CTCFL in an addicted myeloid cancer cell line modulates the expression of multiple protein coding and ncRNA genes
por: Teplyakov, Evgeny, et al.
Publicado: (2017)

Immune Determinants of the Association between Tumor Mutational Burden and Immunotherapy Response across Cancer Types
por: Sinha, Neelam, et al.
Publicado: (2022)

Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors
por: Liu, Qinghai, et al.
Publicado: (2009)

Efficacy of ATR inhibitors as single agents in Ewing sarcoma
por: Nieto-Soler, Maria, et al.
Publicado: (2016)

Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells
por: Suzuki, Rikio, et al.
Publicado: (2015)

Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor
por: Yingling, Jonathan M., et al.
Publicado: (2017)

Rare Germline Variants in ATM Predispose to Prostate Cancer: A PRACTICAL Consortium Study
por: Karlsson, Questa, et al.
Publicado: (2021)

Defining a therapeutic window for kinase inhibitors in leukemia to avoid neutropenia
por: McArthur, Kate, et al.
Publicado: (2017)

A Novel Role for CCL3 (MIP-1α) in Myeloma-induced Bone Disease via Osteocalcin Downregulation and Inhibition of Osteoblast Function
por: Vallet, Sonia, et al.
Publicado: (2011)

Targeting MUC1-C suppresses polycomb repressive complex 1 in multiple myeloma
por: Tagde, Ashujit, et al.
Publicado: (2017)

BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant glioma
por: Ishida, Chiaki Tsuge, et al.
Publicado: (2017)

Selective HDAC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor models
por: Huang, Pengyu, et al.
Publicado: (2016)

Fasting potentiates the anticancer activity of tyrosine kinase inhibitors by strengthening MAPK signaling inhibition
por: Caffa, Irene, et al.
Publicado: (2015)

LIM kinase inhibitors disrupt mitotic microtubule organization and impair tumor cell proliferation
por: Mardilovich, Katerina, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_n5jlon0d23t095ij9hg682l3g7